NAM
PCRX icon

Nexpoint Asset Management’s Pacira BioSciences PCRX Stock Holding History

Nexpoint Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,550
Closed -$291K – 190
2020
Q2 		$291K Sell
5,550
-1,200
-18% -$50.2K 0.07% 151
2020
Q1 		$226K Sell
6,750
-9,500
-58% -$395K 0.04% 181
2019
Q4 		$736K Hold
16,250
– – 0.06% 161
2019
Q3 		$619K Buy
+16,250
New +$649K 0.04% 230

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Nexpoint Asset Management's PCRX Position: Q3 2020 in Review

Nexpoint Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 5,550 shares — an estimated $291K sold.

Nexpoint Asset Management first reported a position in PCRX in Q3 2019 and held it in 4 quarters. The position peaked at $736K in Q4 2019. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

  • Nexpoint Asset Management reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
  • Nexpoint Asset Management sold 5,550 Pacira BioSciences shares in Q3 2020, an estimated $291K.
  • Nexpoint Asset Management first reported a position in Pacira BioSciences in Q3 2019 and held it in 4 quarters.
  • Nexpoint Asset Management's Pacira BioSciences position peaked at $736K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Nexpoint Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.